Drugs in ATC Class S02B

Up to Top Level ATC Classes

Up to S - Sensory organs

Up to S02 - OTOLOGICALS

Subclasses in ATC: S02B - CORTICOSTEROIDS

S02BA - Corticosteroids

ATC Class S02B (Corticosteroids) Market Dynamics and Patent Landscape (Ophthalmic, Otic, Nasal Drop/Topical Steroid Products)

Last updated: June 12, 2026

ATC class S02B corticosteroids cover mainly ophthalmic and otic anti-inflammatory steroid drops, suspensions, and combinations. The patent landscape is dominated by (1) branded active-molecule patents that expired in earlier cycles for multiple legacy steroids, (2) formulation and device patents that extend exclusivity through viscosity, micronization, preservative systems, and sustained-release inserts, and (3) indication- and method-of-use patents (post-surgical inflammation, uveitis subtypes, otitis externa, allergic and inflammatory conditions). Market dynamics are shaped by generic penetration after LOE in ophthalmic steroids, frequent “Authorized Generic” strategies, and payer-driven substitution to the lowest net-cost steroid on formulary. Litigation is recurring but localized, typically around Orange Book-listed formulation and use patents, and around Paragraph IV certifications tied to specific NDC presentations.

Which patents protect ATC S02B corticosteroids?

Core answer: Protection usually comes from active ingredient composition-of-matter (older molecules), followed by newer formulation, preservative/vehicle, particle size, and delivery patents, plus use patents tied to surgery or disease states. For combination products (steroid plus antibiotic/antiallergy), patents expand across each component and the combined regimen.

What product types fall under S02B?

S02B is corticosteroids in the ATC system used broadly across local anti-inflammatory therapy. Commercially, most significant “S02B-like” portfolios in practice sit in:

• Ophthalmic corticosteroid drops and suspensions (post-operative inflammation, uveitis, keratitis inflammatory episodes where indicated)
• Otic corticosteroid preparations for inflammatory ear conditions
• Combination ophthalmic/otic products that add anti-infectives or vasoconstriction/antihistamine components depending on jurisdiction and labeling

How is the patent estate structured in this class?

Patent estate pattern by layer

1. Composition-of-matter (MoA/CoM) for the steroid active
   • Usually expired or near-expiry for legacy corticosteroids.
   • Newer “next-gen” steroid analogs can have later CoM, but S02B is still dominated by established molecules.
2. Formulation patents
   • Micronization/particle size and crystal form
   • Vehicle and viscosity (tears and retention)
   • Preservative systems (benzalkonium chloride alternatives, lower irritation systems)
   • pH and buffer systems for ocular tolerance
   • Osmolality and tonicity
   • Suspending agents and stability
3. Delivery and device patents
   • Sustained-release intravitreal or periocular approaches exist adjacent to S02B but can be cross-listed by mechanism and route.
   • For topical ocular drops, retention-improving devices and drop composition patents are common.
4. Method-of-use and indication patents
   • Dosing regimens (frequency and taper schedules)
   • Post-surgical treatment windows
   • Subgroup disease states (uveitis subtypes, inflammation-related indications)
5. Combination product patents
   • If the product includes antibiotic or other adjuncts, patents extend to the combined formulation and treatment use.

Which jurisdictions matter most for exclusivity enforcement?

• United States: Orange Book listing drives generic entry risk. Patent assertions typically target listed formulation/use patents.
• Europe: Supplementary Protection Certificates (SPCs) and local formulation exclusivity matter, and national litigation affects launch.
• United Kingdom/Canada/Australia: Similar exclusivity mechanics; patent infringement actions determine launch timing.

How does the S02B patent estate extend beyond active ingredient expiry?

Core answer: For many S02B steroids, active-ingredient exclusivity ends early; extension comes via formulation, preservative system, and device/vehicle retention patents, plus use patents tied to dosing or surgical protocols.

What formulation elements are most litigated?

• Preservative package and compatibility with steroid solubility
• Particle size and suspension stability
• Vehicle viscosity and ocular surface residence time
• Freeze-thaw and shelf-life stability
• Osmotic profile to reduce stinging and corneal penetration differences

What delivery concepts create IP that slows generics?

• Sustained or extended release approaches (adjacent to, and sometimes overlapping with S02B by therapeutic use)
• Customized viscosities and retention mechanisms
• Dropper/device integrated patents that control delivery characteristics

Where do method-of-use patents usually sit in S02B?

• Post-cataract surgery inflammation schedules
• Post-keratoplasty or corneal inflammation regimens
• Otic inflammation dosing taper schedules
• Combination therapy sequences (when a steroid is paired with antibiotic or other agents)

When do ATC S02B corticosteroids lose exclusivity?

Core answer: Timelines vary by molecule and specific NDC presentation. In this class, generics typically enter after Orange Book-listed formulation/use patents expire or after settlement-triggered “carve-outs.” For many older steroid actives used in ophthalmic products, the market already sits largely in the post-LOE phase, leaving formulation-specific barriers as the main gate.

What determines the “last-to-expire” outcome?

• The latest expiration date among:
  • Composition-of-matter patents (if still active)
  • Formulation patents listed in the Orange Book
  • Method-of-use patents listed in the Orange Book
• Patent term adjustments and pediatric exclusivity (where applicable)
• SPC expiry and national phase in Europe

What drives staggered generic entry in this class?

• Different NDC presentations (strength, suspension vs solution, preservative type, bottle size)
• Different preservatives or suspending agents
• Different dosing schedules
• Different combinations (steroid-only vs antibiotic-steroid products)

What is the Orange Book status of S02B corticosteroids?

Core answer: Orange Book status varies widely by presentation. The practical pattern is:

• Many steroid drops have multiple Orange Book listings for formulation and use.
• Generic launch timing hinges on the specific listed patents for the target NDC presentation, not just the active ingredient.

Orange Book-driven risk lens

For any intended generic filing, the risk stack usually includes:

• Whether the relevant patents are listed for the exact NDC strength/formulation
• Whether a Paragraph IV notice targets those patents
• Whether the brand has a valid, enforceable Orange Book patent tied to the same presentation

What patent litigation affects generic entry for S02B corticosteroids?

Core answer: Litigation centers on formulation/use patents listed for the Orange Book product. Typical defenses involve validity and infringement, while typical generic countermeasures focus on non-infringement and invalidity based on obviousness, lack of written description, or prior art.

What litigation outcomes matter commercially?

• Automatic 30-month stay after Paragraph IV filing (U.S.)
• Settlement agreements that delay launch or allow early launch with carve-outs
• Design-around (different formulation, preservative system, or dosing) that avoids infringement
• Judgment on the merits enabling “immediate” generic entry or re-filing

Where do settlements commonly create “entry windows”?

• Brands often secure settlements that delay at least one key NDC presentation.
• Generics can sometimes launch non-designated strengths or pack sizes earlier depending on the settlement terms.

Which companies are challenging S02B corticosteroids, and how?

Core answer: Generic challengers are typically firms with ophthalmic portfolios. They pursue Paragraph IV filings on formulation/use patents for specific NDCs and then either litigate through the 30-month window or negotiate settlements.

Common challenger strategies

• File for FDA approval with a bioequivalence approach suited to topical ocular/otic products
• Certify to patents with Paragraph IV where the generic can argue non-infringement or invalidity
• Offer formulations that attempt to avoid infringement by changing excipient systems, particle size targets, or preservative packages

Brand enforcement posture

• Maintain Orange Book listings to anchor injunction leverage
• Assert the subset of patents most likely to survive validity attacks
• Negotiate settlements aligned with formulation-specific patents rather than broad CoM estates

How strong is the patent estate for ATC S02B corticosteroids?

Core answer: Patent strength is presentation-dependent. The active steroid CoM is often weak in enforcement because many legacy actives are old. The enforceable strength tends to shift to formulation and method-of-use patents that are specific and harder to design around without tradeoffs in product performance or stability.

Strength drivers

• Claims that tie to measurable formulation characteristics (particle size, stability, preservative system)
• Narrow method-of-use claims tied to dosing regimens
• Patent families that include late priority filings for formulation improvements

Weakness patterns

• Broad claims that face obviousness attacks
• Prior-art saturation for well-known ophthalmic steroid vehicles
• Generic design-around feasibility when the brand’s patent scope is limited to specific excipients

What formulations are protected by S02B corticosteroid patents?

Core answer: The most frequently protected formulations are suspensions and preservative-managed drops where vehicle and suspension mechanics affect efficacy and tolerability.

Formulation categories that typically receive coverage

• Suspension vs solution variants
• Different preservative systems
• Different viscosity agents
• Different buffering and pH ranges
• Different particle/crystal forms for suspension stability

Combination formulation coverage

If the S02B product is paired with an antibiotic/adjunct:

• Patents can cover combination ratios
• Stability and compatibility between components
• Method-of-use for specific post-operative windows

How do S02B corticosteroids compare with adjacent ophthalmic steroid patents?

Core answer: S02B sits within a larger ecosystem of ophthalmic anti-inflammatory IP. The competitive differentiators often come from:

• Device or delivery improvements
• Sustained-release platforms adjacent to topical steroids
• Combination regimens (steroid plus antimicrobial) that create additional patent layers

Practical IP overlap

• Topical steroid patents often cross-reference:
  • post-operative anti-inflammatory protocols
  • inflammation grading endpoints tied to clinical outcomes
• Sustained-release and implant technologies are more frequently protected in separate IP families but compete for the same treatment space.

What generic entry risks exist for S02B corticosteroids?

Core answer: Entry risk is highest for presentations where Orange Book-listed formulation/use patents are either close to expiration or already adjudicated/settled. Risk is lower where the brand maintains multiple late-expiring formulation patents tied to the exact NDC.

Risk checklist for launch planning

• Patent-by-patent mapping to the exact NDC strength and formulation
• Confirming whether formulation design-around can preserve stability and ocular tolerance
• Assessing litigation posture: whether the brand is actively asserting or settled previously for that product line
• Monitoring FDA labeling and any post-approval changes that could alter infringement analysis

What is the competitive landscape for S02B corticosteroids?

Core answer: The landscape is split between:

• Branded “anchor” ophthalmic steroid products with Orange Book listings
• Multiple generic steroid drops and suspensions for common post-operative and inflammatory indications
• Combination products where antibiotic add-ons create additional IP and formulary positioning

Commercial dynamics shaping IP value

• Payer substitution pressure after LOE
• Multi-source competition drives net price erosion
• Small differences in formulation and tolerability matter for retention despite generic availability

Key Takeaways

• S02B corticosteroids rely on a layered patent estate: formulation and method-of-use protections often matter more than legacy steroid composition claims.
• Orange Book status and NDC-level patent listings are the decisive variables for generic entry timing in the U.S.
• Patent litigation and settlements typically target specific formulation/use patents tied to the exact product presentation, creating staggered launch outcomes.
• Market competition is driven by payer substitution and net price erosion, pushing brands to defend value through formulation-specific exclusivity and legal leverage.

FAQs

1. Do Paragraph IV challenges for ophthalmic steroids under S02B typically target formulation or method-of-use patents?
2. How do preservative changes in generic ocular suspensions affect infringement risk for steroid formulations?
3. What settlement terms most often allow partial early launch of generic S02B corticosteroids?
4. When a brand switches excipients post-approval, how does that affect Orange Book patent linkage and infringement analysis?
5. Are otic corticosteroid products in S02B more exposed to generic competition than ophthalmic presentations?

References

No sources were provided in the prompt, and no drug-specific Orange Book, patent, or litigation identifiers were included for citation-backed accuracy.